drugset
drugset / Trial / NCT05219838

Binding and Effects of Lu AG06466 in the Brain of Healthy Men

NCT05219838 ↗

Phase 1 Completed 8 enrolled H. Lundbeck A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is being done to learn about the binding of Lu AG06466 and its major breakdown product (Lu AG06988) in the brain of healthy men having received multiple doses of Lu AG06466. As the binding will result in inhibition of an enzyme in the endocannabinoid system called monoacylglycerol lipase (MAGL), the effects on this system will be evaluated both in the blood and cerebrospinal fluid and compared to the binding in the brain.

Timeline

Start
2022-01-18
Primary completion
2022-08-18
Completion
2022-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AG06466 Unknown — Oral

Indications

No indication recorded.